<scp>Anti‐CD20</scp> monoclonal antibody therapy in postpartum women with neurological conditions

Abstract

These confirm minimal transfer of mAb into breastmilk. Anti-CD20 mAb therapy stabilizes MS activity before conception to the postpartum period, and postpartum treatments appears to be safe and well-tolerated for both mother and infant.